Diagnosis and therapy in advanced cancer of the esophagus and the gastroesophageal junction

Current Opinion in Gastroenterology

Volumn 22, Issue 4, 2006, Pages 437-441

  Lerut, Toni ^a   Coosemans, Willy ^a   Decker, Georges ^a   De Leyn, Paul ^a   Moons, Johnny ^a   Nafteux, Philippe ^a   Van Raemdonck, Dirk ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Adjuvant; Cancer; CT; Diagnosis; Esophagus; EUS; Gastroesophageal junction; Multimodal neo adjuvant; PET scan; Prediction; Response; Surgery; Treatment

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; BEVACIZUMAB; BORTEZOMIB; CARBOGEN; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERYTHROPOIETIN; FLAVOPIRIDOL; GEFITINIB; MATRIX METALLOPROTEINASE INHIBITOR; MATUZUMAB; NICOTINAMIDE; TIRAPAZAMINE;

ADVANCED CANCER; ASPIRATION BIOPSY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIAGNOSTIC ACCURACY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LOWER ESOPHAGUS SPHINCTER; LYMPHADENECTOMY; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; REVIEW; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

BIOPSY, NEEDLE; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; ENDOSONOGRAPHY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; STOMACH NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33746263800     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000231822.48890.3d     Document Type: Review

References (34)

1. Watt E, Whyte F. The experience of dysphagia and its effect on the quality of life of patients with esophageal cancer. Eur J Cancer Care 2003; 12:183-193.
2. Lightdale CJ, Kulkarni KG. Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol 2005; 23:4483-4489. This is a comprehensive analysis of the value of EUS in staging of esophageal cancer.
3. Zuccaro G Jr, Rice TW, Vargo JJ, et al. Endoscopic ultrasound errors in esophageal cancer. Am J Gastroenterol 2005; 100:1216. The authors describe the difficulties in discriminating between pT1b-T2 and pT3-T4 with misclassification by EUS of disease extent in 15%.
4. Weaver SR, Blachshaw GRJC, Lewis WG, et al. Comparison of special interest computed tomography, endosonography and histopathological stage of oesophageal cancer. Clinical Radiology 2004; 59:499-504.
5. Van Westreenen. Positron emission tomography in staging of esophageal cancer [thesis]. Groningen: University of Groningen. Enschede: Print Partner Ipskamp; 2005.
6. Choi JY, Jang HJ, Shim YM, et al. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med 2004; 45:1843-1850. This study demonstrated the value of PET scan as predictor of prognosis based on absence and presence of PET positive nodes. There were no survivors after esophagectomy in patients with three or more PET positive nodes.
7. Enzinger P, Mayer R. Esophageal cancer. N Engl J Med 2003; 23:2241-2252.
8. Lerut T, Coosemans W, Decker G, et al. Surgical techniques. J Surg Oncol 2005; 92:218-229.
9. Hulscher JB, Van Lanschot JJ. Individualized surgical treatment of patients with adenocarcinoma of the distal esophagus and gastro-esophageal junction. Dig Surg 2005; 22:130-134. This follow-up study of an earlier randomized controlled trial on extended versus no lymphadenectomy indicates a substantial survival benefit favouring extended lymphadenectomy in the subgroup of adenocarcinoma of the esophagus.
10. Tachibana M, Kinugasa S, Yoshimura H, et al. Clinical outcomes of extended esophagectomy with three-field lymph node dissection for esophageal squamous cell carcinoma. Am J Surg 2005; 189:98-109. This study showed a remarkable 5-year survival of 68.9% obtained after three-field lymphadenectomy.
11. Tabira Y, Okuma T, Sakaguchi T, et al. Three-field dissection or two-field dissection? A proposal of a new algorithm for lymphadenectomy. Hepatogastroenterology 2004; 51:1015-1020.
12. Lerut T, Nafteux P, Moons J, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 RO resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004; 240:962-972; discussion 972-974.
13. Malthaner R, Fenlon D. Preoperative chemotherapy for respectable esophageal cancer. Cochrane Database Syst Rev 2003; (4):CD001556.
14. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and metaanalysis. Gut 2004; 53:925-930.
15. Urschel JD, Vasan H. A meta analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185:538-543.
16. Malthaner RA, Wong RK, Rumble RB, Zuraw L. Gastrointestinal Disease Group of Cancer Care Ontario's Program in Evidence-based Care. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline. BMC Cancer 2004; 4:67. This is an extensive review of literature and meta-analysis on different combinations of multimodality treatment. The authors find a benefit at 3 years obtained from induction chemoradiotherapy.
17. Burmeister BH, Smithers BM, Gebski V, et al. For the Trans-Tasman Radiation Oncology Group (TROG) and The Australasian Gasto-Intestinal Trials Group (AGITG). Surgery alone versus chemoradiotherapy followed by surgery for respectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 2005; 6:659-668. This was the most recent large and detailed trial comparing induction chemoradiotherapy with surgery alone. No difference in survival was found except for tumor free survival in the subset of squamous cell carcinoma.
18. Kesler KA, Helft PR, Werner EA, et al. A retrospective analysis of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation therapy followed by surgery or surgery alone. Ann Thorac Surg 2005; 79:1116-1121.
19. Kalha I, Kaw M, Fukami N, et al. The accuracy of endoscopic ultrasound for restaging esophageal carcinoma after chemoradiation therapy. Cancer 2004; 101:940-947.
20. Cerfolio RJ, Bryant AS, Ohja B, et al. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovascular Surg 2005; 129:1232-1241.
21. Wieder HA, Beer AJ, Lordick F, et al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocercinomas of the esophagogastric junction. J Nucl Med 2005; 46:2029-2034. The authors confirm that a PET scan is much more sensitive than a CT scan in assessing tumor response after chemotherapy as early as 2 weeks after initiation of chemotherapy and at all time points.
22. Song SY, Kim JH, Ryu JS, et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2005; 63:1053-1059.
23. Liu HC, Hung SK, Huang CJ, et al. Esophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapy. World J Gastroenterol 2005; 11:5367-5372. This interesting study indicated a survival advantage using adjuvant chemoradiotherapy versus adjuvant radiotherapy alone.
24. Pasini F, de Manzoni G, Pedrazzani C, et al. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol 2005; 16:1133-1139.
25. Nallapareddy S, Wilding GE, Yang G, et al. Chemoradiation is tolerable therapy for older adults with esophageal cancer. Anticancer Res 2005; 25:3055-3060.
26. Rice DC, Correa AM, Vaporciyan AA, et al. Preoperative chemoradiotherapy prior to esophagectomy in elderly patients is not associated with increased morbidity. Ann Thorac Surg 2005; 79:391-397.
27. Tripp P, Malhotra HK, Javle M, et al. Cardiac function after chemoradiation for esophageal cancer: comparison of heart dose-volume histogram parameters to multiple gated acquisition scan changes. Dis Esophagus 2005; 18:400-405.
28. Kato H, Fukuchi M, Manda R, et al. The effectiveness of planned esophagectomy after neoadjuvant chemoradiotherapy for advanced esophageal carcinomas. Anticancer Res 2004; 24:4091-4096.
29. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23:2310-2317. This randomized controlled trial compared definitive chemoradiotherapy and induction chemoradiotherapy plus surgery. There was an equal overall survival but much higher local relapse in the chemoradiotherapy only arm.
30. Ilson DH. Anti-tumour treatment. Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev 2003; 29:525-532.
31. Ryan P, McCarht S, Kelly J, et al. Prevalence of bone marrow micrometastases in esophagogastric cancer patients with and without neoadjuvant chemoradiotherapy. J Surg Res 2004; 117:121-126.
32. Tabernero J, Macarulla T, Ramos FJ, Baselga J. Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 2005; 16:1740-1748.
33. Nozoe T, Ezaki T, Kabashima A, et al. Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus. Am J Surg 2005; 189:110-115.
34. Kaanders JH, Bussink J, van der Kogel AJ. Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol 2004; 14:233-240.